Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 3, 2015, Pages 165-182

  Pojero, Fanny ^a,b   Casuccio, Alessandra ^b   Parrino, Maria Francesca ^a   Cardinale, Giovanni ^c   Colonna Romano, Giuseppina ^b   Caruso, Calogero ^b   Gervasi, Francesco ^a  

^a ARNAS Civico   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Unit of Onco hematology   (Italy)

Author keywords

Monoclonal gammopathies; Multiparameter flow cytometry; Multiple myeloma

Indexed keywords

ALPHA4 INTEGRIN; C REACTIVE PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; UREA; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD19 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLONAL MALIGNANT PLASMA CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETER FLOW CYTOMETRY; MULTIPLE MYELOMA; PLASMA CELL; POLYCLONAL PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION; UREA NITROGEN BLOOD LEVEL; AGED; CANCER STAGING; CELL CLONE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; ANTIGENS, CD19; ANTIGENS, CD45; ANTIGENS, CD56; ANTIGENS, CD58; ANTINEOPLASTIC AGENTS; BIOMARKERS; CLONE CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INTEGRIN ALPHA4; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMA CELLS; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84928370932     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21218     Document Type: Article

References (64)

1. Kyle RA, Rajkumar SV., Multiple myeloma. N Engl J Med 2004; 351: 1860-1873. (Erratum N Engl J Med 2005;352:1163).
2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ, 3rd,. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569.
3. Harousseau JL, Dreyling M., ESMO guidelines working group. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: 155-157.
4. Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, et al.,. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012; 17: 592-606. Epub 2012 May 9. Review. (Erratum in: Oncologist 2012;17:1005).
5. Suzuki K., Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol 2013; 43: 116-1124. Review.
6. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, et al.,. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
7. Harousseau JL, Attal M, Avet-Loiseau H., The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146.
8. Chanan-Khan AA, Giralt S., Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624. Review.
9. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J, Jr, Bos NA,. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 2003; 121: 36-43.
10. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al.,. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438.
11. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR,. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007; 21: 2043-2046.
12. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al.,. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194-4197. (Erratum in: Blood 2007;109:2717).
13. Robillard N, Pellat-Deceunynck C, Bataille R, Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105: 4845-4848.
14. Cao W, Goolsby CL, Nelson BP, Singhal S, Mehta J, Peterson LC., Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol 2008; 129: 926-933.
15. Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Nuñez G, Alonso JM, de Las Heras N, et al.,. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
16. San Miguel JF, Gutierrez NC, Mateo G, Orfao A., Conventional diagnostics in multiple myeloma. Eur J Cancer 2006; 42: 1510-1519.
17. Liu H, Yuan C, Heinerich J, Braylan R, Chang M, Wingard J, Moreb J,. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma 2008; 49: 306-314.
18. Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P., Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol 2009; 132: 728-732.
19. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR., Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008; 141: 135-148.
20. Alcindor T, Kimlinger T, Witzig TE., High expression of CD59 and CD55 on benign and malignant plasma cells. Leuk Lymphoma 2006; 47: 919-921.
21. Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, et al.,. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 2011; 96: 1512-1520.
22. Raja KR, Kovarova L, Hajek R., Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149: 334-351.
23. Kumar S, Kimlinger T, Morice W., Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 2010; 23: 433-451.
24. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C,. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240. Review.
25. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW,. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
26. Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB,. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 2012; 137: 93-100.
27. Conticello C, Giuffrida R, Parrinello N, Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A, Romano A, et al.,. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. Leuk Res 2013; 37: 1616-1621.
28. Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM., Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol 1992; 81: 331-335.
29. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, et al.,. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231-242.
30. Tatsumi T, Shimazaki C, Goto H, Araki S, Sudo Y, Yamagata N, Ashihara E, Inaba T, Fujita N, Nakagawa M,. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 1996; 87: 837-842.
31. Mateo Manzanera G, San Miguel Izquierdo JF, Orfao de Matos A., Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005; 113: 5-24.
32. Pellat-Deceunynck C, Barillé S, Puthier D, Rapp MJ, Harousseau JL, Bataille R, Amiot M,. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647-3653.
33. Helfrich MH, Livingston E, Franklin IM, Soutar RL., Expression of adhesion molecules in malignant plasma cells in multiple myeloma: Comparison with normal plasma cells and functional significance. Blood Rev 1997; 11: 28-38. Review.
34. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE., CD45 expression by bone marrow plasma cells in multiple myeloma: Clinical and biological correlations. Leukemia 2005; 19: 1466-1470.
35. Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA, Davies FE, Child JA, Jack AS, Morgan GJ,. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol 2001; 113: 794-802.
36. Zheng W, Liu D, Fan X, Powers L, Goswami M, Hu Y, Lin P, Medeiros LJ, Wang SA,. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom 2013; 84: 222-228.
37. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, et al.,. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360-376. (Erratum in: Mayo Clin Proc 2013;88:777).
38. Al-Farsi K., Multiple myeloma: An update. Oman Med J 2013; 28: 3-11.
39. Sawyer JR., The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011; 204: 3-12. Review.
40. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, et al.,. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 2014; 38: 371-376.
41. Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA,. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. J Clin Pathol 2012; 65: 823-829.
42. Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L., Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B 2011; 80: 318-323.
43. Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de las Heras N, et al.,. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114: 4369-4372.
44. Kovarova L, Buresova I, Buchler T, Suska R, Pour L, Zahradova L, Penka M, Hajek R,. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma 2009; 56: 526-532.
45. Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J, Borrego D, Rodríguez MJ, Ortega F, Hernandez J, et al.,. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005; 19: 449-455.
46. Durie BG, Salmon SE., A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
47. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al.,. International staging system for multiple myeloma. J Clin Oncol 2005;, 23,: 3412-3420. (Erratum J Clin Oncol 2005;23:6281).
48. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, et al.,., Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154: 32-75.
49. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC., A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007; 21: 2046 Sep
50. Hulspas R, O'Gorman MR, Wood BL, Gratama JW, Sutherl DR., Considerations for the control of background fluorescence in clinical flow cytometry. Cytometry B 2009; 76B: 355-364. Nov
51. Jones D, editor. Neoplastic Hematopathology: Contemporary Hematology. Experimental and Clinical Approaches, 1st ed. New York: Humana Press; 2010
52. Bain BJ., Bone marrow aspiration. J Clin Pathol. 2001; 54: 657-663. Review.
53. Clark G, editor. Staining Procedures, 3rd ed. Baltimore, Maryland: Williams & Wilkins; 1973.
54. van Dongen JJ, Orfao A,; EuroFlow Consortium. EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia 2012; 26: 1899-1907.
55. Wright CW, Rumble JM, Duckett CS., CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007; 282: 10252-10262.
56. Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G, Preffer F,. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom 2010; 78: 231-238.
57. Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, Miguel JF, Orfao A,. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78: 239-252.
58. Llinàs L, Lázaro A, de Salort J, Matesanz-Isabel J, Sintes J, Engel P., Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett 2011; 134: 113-121.
59. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, Schlossman SF., CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA 1997; 94: 6346-6351.
60. Tagoug I, Plesa A, Dumontet C., Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol 2013; 706: 11-16.
61. Olteanu H, Harrington AM, Kroft SH., CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: Clinicopathologic features and comparison with plasma cell myeloma. Am J Clin Pathol 2012; 138: 867-876.
62. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, et al.,. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744.
63. Moreau P, Robillard N, Jégo G, Pellat C, Le Gouill S, Thoumi S, Avet-Loiseau H, Harousseau JL, Bataille R,. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 2006; 132: 168-170.
64. Schmidt-Hieber M, Pérez-Andrés M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, Vidriales MB, Matarraz S, San Miguel JF, Orfao A,. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011; 96: 328-332.